>- The higher complete response rate with APF-530 vrs Aloxi in treatment experienced vrs treatment naive patients (patients with prior chemo experience tend to have greater nausea/vomiting).
- The higher response rates vrs Aloxi with the highly emetogenic chemo agent Cisplatin, for both acute onset and delayed onset CINV.<
The trial was for non-inferiority, so I don't think you get to claim that the response rates were superior.
Market Data 
Markets 
AI
